Who makes SB204 8% or 12%?

SB204 8% or 12% is developed by Novan, Inc..

Last reviewed 2026-04-19 · How we verify

SB204 8% or 12%

Novan, Inc. · Phase 1 active Small molecule

At a glance

Generic name	SB204 8% or 12%
Also known as	NVN1000
Sponsor	Novan, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SB204 8% or 12% CI brief — competitive landscape report
SB204 8% or 12% updates RSS · CI watch RSS
Novan, Inc. portfolio CI